- Trials with a EudraCT protocol (268)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
268 result(s) found for: Administration site reactions.
Displaying page 1 of 14.
| EudraCT Number: 2009-015175-27 | Sponsor Protocol Number: NVI-250 | Start Date*: 2010-02-16 |
| Sponsor Name:Netherlands Vaccine Institute | ||
| Full Title: Immunogenicity and safety of intradermal injection of reduced dose Inactivated Poliovirus vaccine (IPV) with a jet injector in healthy adults | ||
| Medical condition: The vaccine in this healthy volunteer trial is indicated to prevent poliomyelitis. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2025-000441-15 | Sponsor Protocol Number: C4601012 | Start Date*: 2026-02-04 |
| Sponsor Name:Pfizer, Inc. | ||
| Full Title: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY OF A 6-VALENT OspA-BASED LYME DISEASE VACCINE (VLA15) IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | ||
| Medical condition: Lyme borreliosis | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2015-001648-12 | Sponsor Protocol Number: OVG2015/02 | Start Date*: 2015-09-03 |
| Sponsor Name:University of Oxford | ||
| Full Title: A phase II, open label trial to describe immune and transcriptional responses to MF59 adjuvanted trivalent influenza vaccine (ATIV) in 13-24 month healthy children and adults 18-65 years | ||
| Medical condition: This trial is investigating healthy children and adult's gene expression and immune response to the Fluad (MF59)-adjuvanted trivalent influenza vaccine and also comparing these to the local and gen... | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-004590-30 | Sponsor Protocol Number: R10933-10987-COV-2121 | Start Date*: 2022-09-23 | |||||||||||
| Sponsor Name:Regeneron Pharmaceuticals Inc. | |||||||||||||
| Full Title: A Phase 2a, Open-Label Study Assessing Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Single-Dose Subcutaneous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab and Imdevim... | |||||||||||||
| Medical condition: Coronavirus disease 2019 | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-001587-31 | Sponsor Protocol Number: A001-2PX | Start Date*: 2005-06-07 |
| Sponsor Name:SantoSolve AS | ||
| Full Title: | ||
| Medical condition: Patients with fibromyalgia diagnosed according to ACR classification (1990) and with chronic pain at defined symmetrical body areas. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-002546-49 | Sponsor Protocol Number: SCP-01-001 | Start Date*: 2014-10-03 |
| Sponsor Name:scPharmaceuticals Inc | ||
| Full Title: A single center, randomized, open-label, cross-over exploratory study to evaluate the pharmacodynamic and pharmacokinetic response to a subcutaneous administration or oral administration of furosem... | ||
| Medical condition: Fluid overload in heart failure | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2017-003416-38 | Sponsor Protocol Number: TMP-0916_02 | Start Date*: 2018-04-05 | |||||||||||
| Sponsor Name:Fraunhofer Gesellschaft for its Institute Fraunhofer Institute for Molecular Biology and Applied Ecology (IME) | |||||||||||||
| Full Title: Randomised, open lable, active controlled clinical trial to demonstrate safety and efficacy of an i.v. administration of Polyglucoferron compared to i.v. Ferric Carboxymaltose and oral iron substit... | |||||||||||||
| Medical condition: preoperative iron deficiency anaemia in patients with planned elective non-cardiac surgery | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-001471-20 | Sponsor Protocol Number: MET35 | Start Date*: 2018-07-10 | |||||||||||
| Sponsor Name:Sanofi Pasteur Inc. | |||||||||||||
| Full Title: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children 2 to 9 Years of Age | |||||||||||||
| Medical condition: Healthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y or W) | |||||||||||||
|
|||||||||||||
| Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-005566-33 | Sponsor Protocol Number: VYF03 | Start Date*: 2021-07-08 | |||||||||||
| Sponsor Name:Sanofi Pasteur | |||||||||||||
| Full Title: Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to Stamaril® in Adults | |||||||||||||
| Medical condition: Prevention of yellow fever | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) FI (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-003135-36 | Sponsor Protocol Number: CYD67 | Start Date*: 2019-10-31 |
| Sponsor Name:Sanofi Pasteur SA | ||
| Full Title: Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially with Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia | ||
| Medical condition: Dengue Fever Dengue Hemorrhagic Fever Human Papillomavirus Disease | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2021-000104-38 | Sponsor Protocol Number: MEQ00073 | Start Date*: 2021-06-17 | |||||||||||
| Sponsor Name:Sanofi Pasteur | |||||||||||||
| Full Title: A Phase IIIb, Open-label, Multi-center Study to Evaluate the Immunogenicity and Safety of a Booster Dose and Describe the Immune Persistence of MenACYW Conjugate Vaccine with 5- and/or 10-year Boos... | |||||||||||||
| Medical condition: Meningococcal infection | |||||||||||||
|
|||||||||||||
| Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: FI (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-000577-11 | Sponsor Protocol Number: VAP00027 | Start Date*: 2022-07-29 | |||||||||||
| Sponsor Name:Sanofi Pasteur Inc | |||||||||||||
| Full Title: Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years | |||||||||||||
| Medical condition: | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) PL (Completed) DK (Completed) CZ (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-003870-21 | Sponsor Protocol Number: MG0020 | Start Date*: 2023-07-25 | |||||||||||
| Sponsor Name:UCB Biopharma SRL | |||||||||||||
| Full Title: An open-label, crossover study to evaluate rozanolixizumab self-administration by study participants with generalized Myasthenia Gravis | |||||||||||||
| Medical condition: Generalized Myasthenia Gravis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) ES (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-000994-22 | Sponsor Protocol Number: CYD71 | Start Date*: 2019-06-13 |
| Sponsor Name:Sanofi Pasteur SA | ||
| Full Title: Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® in Healthy Female Subjects Aged 9 to 14 Years in Mexico | ||
| Medical condition: Dengue Fever Dengue Hemorrhagic Fever Human Papillomavirus Disease | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2019-003136-23 | Sponsor Protocol Number: CYD66 | Start Date*: 2020-02-12 |
| Sponsor Name:Sanofi Pasteur SA | ||
| Full Title: Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially with Adacel® in Healthy Subjects Aged 9 to 60 Years in the Philippines | ||
| Medical condition: Dengue Fever Dengue Hemorrhagic Fever | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2008-004611-35 | Sponsor Protocol Number: p53.08.001 | Start Date*: 2009-01-22 |
| Sponsor Name:Leiden University Medical Center | ||
| Full Title: Phase I/II study: on the toxicity and effects of combining the p53 synthetic long peptides vaccine with either Imiquimod or Interferon-alfa to induce polarized p53-specific immunity in patients tre... | ||
| Medical condition: adult both male and femal patients treated for colorectal cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-003439-12 | Sponsor Protocol Number: TMP-0916_03 | Start Date*: 2018-02-19 | |||||||||||
| Sponsor Name:Fraunhofer Gesellschaft for its Institute Fraunhofer für Translationale Medizin und Pharmakologie (ITMP) | |||||||||||||
| Full Title: Safety and efficacy of postoperative i.v. iron substitution with Polyglucoferron compared to Ferric Carboxymaltose and oral iron in patients with diagnosed iron deficiency who develop anaemia pre- ... | |||||||||||||
| Medical condition: pre-operative iron deficiency in patients with planned elective surgery and pre-/post-operative iron deficiency anamia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-000898-23 | Sponsor Protocol Number: 2019/KEP/218 | Start Date*: 2019-08-01 | |||||||||||
| Sponsor Name:London School of Hygiene and Tropical Medicine | |||||||||||||
| Full Title: Pharmacokinetics of intramuscular tranexamic acid in trauma patients: a clinical trial | |||||||||||||
| Medical condition: Traumatic haemorrhage | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-003063-34 | Sponsor Protocol Number: GSDL_DE_17 | Start Date*: 2017-12-11 | |||||||||||
| Sponsor Name:Lofarma S.p.A. | |||||||||||||
| Full Title: A double-blind, placebo-controlled dose-escalation study of carbamylated monomeric tree pollen drops in patients with a history of allergic rhinoconjunctivitis. | |||||||||||||
| Medical condition: Treatment of tree pollen-induced allergic rhinoconjunctivitis | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-003070-31 | Sponsor Protocol Number: VAN00002 | Start Date*: 2022-01-24 | |||||||||||
| Sponsor Name:Sanofi Pasteur Inc. | |||||||||||||
| Full Title: Safety and Immunogenicity of an Investigational Multicomponent Meningococcal Group B Vaccine in Adults, Adolescents, Toddlers, and Infants | |||||||||||||
| Medical condition: Invasive Meningococcal Disease (IMD) | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.